Artículo

Applications and impact of telemedicine for persons with epilepsy: a scoping review

Sahu, Jitendra Kumar ; Coan, Ana Carolina ; Chan, Josephine ; Jocic Jakubi, Bosanka ; Dhir, Pooja ; Niveditha, Mamidi ; Devi, Nagita ; Singh, Mamta Bhushan ; Shafer, Patricia Osborne ; Hsiang-Yu, Yu ; Ali, Amza ; Yoo, Ji Yeoun ; Zelano, Johan ; Sarfo, Fred Stephen ; Fortini, Pablo Sebastián ; Gwer, Samson Awili ; Rivera, Yanin ; Kissani, Najib ; Caraballo, Roberto Horacio Icon; Bansal, Dipika ; Trinka, Eugen ; Cross, J Helen ; Samia, Pauline

Otros responsables

Fecha

03/2026

Editorial

W B Saunders Co Ltd

Revista

Seizure

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

1059-1311

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Telemedicine is emerging as a promising strategy to overcome geographical and specialist access constraints in epilepsy care. This scoping review, conducted by the International League Against Epilepsy (ILAE) Telemedicine Task Force, aimed to map the existing evidence on the applications, effectiveness, and challenges of telemedicine in epilepsy management. A systematic search of PubMed, Embase, and Web of Science, conducted up to May 2025 without language restrictions, identified original studies evaluating telemedicine for epilepsy diagnosis, management, or follow-up. Data were extracted and synthesized narratively. Of the 201 included studies, approximately 70% originated from high-income settings. Evidence demonstrated diagnostic accuracy ranging from 75% to 97%, cost savings of about US$30 per consultation, and high satisfaction levels among patients (87-95%) and physicians (74-94%). Telemedicine also reduced no-shows by 45%, ensuring continuity of care during healthcare disruptions such as the COVID-19 pandemic. Overall, telemedicine is a feasible adjunct to conventional epilepsy care, enhancing access, accuracy, and cost-effectiveness. To substantiate its role in diverse settings, well-designed randomized controlled trials are needed to evaluate long-term outcomes, equity, and sustainability.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa